Grant of Options and PDMR Dealing

RNS Number : 7652T
MaxCyte, Inc.
22 March 2023
 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Grant of Options and PDMR Dealing

 

Gaithersburg, Maryland - 22 March 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a  leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research , announces that on 20 March 2023, a total of 480,000 options of common stock in the Company ("Common Stock") were granted to PDMRs of the Company ("Option Grants"). Details of the Option Grants are given below:

 

Option Grants to PDMRs


Doug Doerfler

400,000

Rekha Hemrajani

40,000

Yasir Al-Wakeel

40,000

Total

480,000

 

Options granted to Doug Doerfler vest 12/48th of the total grant one year after date of grant, and thereafter vest 1/48 th  per month for 36 months after the date of grant.

 

Of the option granted to Rekha Hemrajani and Yasir Al-Wakeel, Non-Executive Directors of the Company, 23,333 of the Option Grants vested on the date of the grant, and the remaining 16,667 shares will vest in 15 equal monthly installments thereafter, beginning on April 14, 2023.

 

The Option Grants have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 20 March 2023, being $4.19.

 

About MaxCyte

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx®, STx® GTx® and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Learn more at  maxcyte.com  and follow us on  Twitter  and  LinkedIn .

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

+1 415-937-5400

ir@maxcyte.com

 

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500

 

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation®technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™,GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn .

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

a)  Doug Doerfler

b)  Rekha Hemrajani

c)  Yasir Al-Wakeel

2

 

Reason for the notification

 

a)

 

Position/status

 

 

a)  President and CEO 

b)  Non-Executive Director

c)  Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

MaxCyte Inc.

b)

 

LEI

 

 

54930053YHXULRFCU991

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

 

Nature of the transaction

 

 

Grant of options of common stock

c)

 

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




a)  $4.19

400,000




b)  $4.19

40,000




c)  $4.19

40,000







d)

 

Aggregated information




- Aggregated volume

480,000



- Price

$4.19



e)

 

Date of the transaction

 

 

March 20, 2023

f)

 

Place of the transaction

 

 

USStock Exchange, Nasdaq

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBRGDXXGDDGXB
UK 100

Latest directors dealings